[HT-06] Hot Topics 06 New diagnostic and therapy strategies for PSP/CBD

[HT-06-1] Current status and future perspective of clinical diagnosis of PSP/CBD

^○Irene Litvan (US San Diego, Department of Neuroscience, USA)

Dr. Litvan is the Tasch Endowed Professor of Neurology at the University of California San Diego (UCSD) and Director of the Parkinson Disease Movement Disorder Center, designated as Parkinson Foundation Center of Excellence, Research Center of Excellence in Lewy Body Dementia and CurePSP Center of Care. She is a neurologist specialized in movement disorders, dementia and neuroepidemiology. Her major research goal is to identify symptomatic and biological therapies that can improve the quality of life of patients with neurodegenerative disorders presenting with parkinsonism and/or dementia. For which she has focused her research in improving or developing neuropathologic and afterwards clinical diagnostic criteria that would allow to identify these patients more accurately and finding robust diagnostic and outcome biomarkers. For more than 30 years, she has led or participated in several multicenter studies or international Task Forces to develop clinical and neuropathologic diagnostic criteria for parkinsonian and/or dementia neurodegenerative disorders (PSP, CBD, MSA, DLB, PD, PD-MCI, Prodromal PD and PDD) for which she received the National Institutes of Health merit award and recently the American Academy of Neurology Movement Disorder Research Award and Uruguayan National Academy of Medicine entrance.